Literature DB >> 9578190

The airway effects of stopping regular oral theophylline in patients with asthma.

J A Bennett1, J Thompson Coon, I D Pavord, P J Wilding, A E Tattersfield.   

Abstract

AIMS: We investigated whether the deterioration in asthma control reported following cessation of theophylline was due to tolerance to theophylline.
METHODS: Eighteen subjects with mild stable asthma were given oral theophylline 10 mg kg(-1) day(-1) or placebo for 2 weeks in a double-blind crossover study. FEV1 and PD20 histamine were measured before and 8 h after the first dose of treatment and 8, 32 and 56 h after the final dose. PD20 AMP was measured before treatment and 9 h after the final dose.
RESULTS: Six patients did not tolerate theophylline. In the other 12 subjects there were no differences between treatments in daily PEF, symptom scores, rescue bronchodilator use, PD20 histamine or FEV1 up to 8 h post treatment. Following withdrawal of theophylline there were significantly lower values for mean FEV1 (mean difference 0.151, 95% CI 0.03, 026) and PD20 AMP compared to placebo but no difference in other end points.
CONCLUSIONS: The small rebound deterioration in lung function following regular treatment with therapeutic doses of oral theophylline is consistent with the development of tolerance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9578190      PMCID: PMC1873970          DOI: 10.1046/j.1365-2125.1998.t01-1-00691.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Need for theophylline in severe steroid-requiring asthmatics.

Authors:  M Brenner; R Berkowitz; N Marshall; R C Strunk
Journal:  Clin Allergy       Date:  1988-03

2.  Reduced responsiveness of adenylate cyclase in alveolar macrophages from patients with asthma.

Authors:  M Bachelet; D Vincent; N Havet; R Marrash-Chahla; A Pradalier; J Dry; B B Vargaftig
Journal:  J Allergy Clin Immunol       Date:  1991-09       Impact factor: 10.793

3.  Unstable asthma and theophylline.

Authors:  M Stern; D M Geddes; J V Collins; T Evans
Journal:  BMJ       Date:  1991-11-23

4.  Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma.

Authors:  A S Vathenen; A J Knox; A Wisniewski; A E Tattersfield
Journal:  Am Rev Respir Dis       Date:  1991-06

5.  Withdrawal syndrome after the double-blind cessation of caffeine consumption.

Authors:  K Silverman; S M Evans; E C Strain; R R Griffiths
Journal:  N Engl J Med       Date:  1992-10-15       Impact factor: 91.245

6.  Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity.

Authors:  T J Torphy; H L Zhou; L B Cieslinski
Journal:  J Pharmacol Exp Ther       Date:  1992-12       Impact factor: 4.030

7.  Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy.

Authors:  J Kidney; M Dominguez; P M Taylor; M Rose; K F Chung; P J Barnes
Journal:  Am J Respir Crit Care Med       Date:  1995-06       Impact factor: 21.405

Review 8.  Theophylline in the management of asthma: time for reappraisal?

Authors:  P J Barnes; R A Pauwels
Journal:  Eur Respir J       Date:  1994-03       Impact factor: 16.671

Review 9.  Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants.

Authors:  K F Rabe; H Magnussen; G Dent
Journal:  Eur Respir J       Date:  1995-04       Impact factor: 16.671

10.  Protective effect of theophylline on bronchial hyperresponsiveness in patients with allergic rhinitis.

Authors:  M Aubier; J Levy; C Clerici; F Neukirch; F Cabrières; D Herman
Journal:  Am Rev Respir Dis       Date:  1991-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.